DeepOcean Group Holding AS Forms Board of Directors
15.7.2011 13:00:51 CEST | Business Wire | Press release
Thomas Thune Andersen to Serve as Chairman
Board Comprised of Three Industry Veterans and Two Seasoned Professionals
DeepOcean Group Holding AS (“DeepOcean Group” or the “Company”), an integrated provider of subsea, trenching and marine support vessels and services, today announced the formation of its Board of Directors. The Board is currently comprised of five directors, including three industry veterans, as well as two representatives of the Company's new shareholders:
- Thomas Thune Andersen, Chairman of the Board;
- Bart H. Heijermans, Director;
- Harald J. Norvik, Director;
- Arvid Trolle, Director; and
- David N. Weinstein, Director.
“We are pleased to welcome these highly qualified directors to DeepOcean Group,” said Mr. John R. Castellano, interim Chief Executive Officer, commenting on the recent appointments. “Each candidate provides the Company with valuable perspective and brings with them a wealth of experience. They will provide the insight and expertise to grow our company and create an industry leader. As Chairman, Thomas brings a deep understanding of the oil and gas industry and a proven track record of success, and under his guidance, the Board is well-positioned to immediately address the strategic needs of the Company. Bart and Harald also have excellent industry management experience and extensive relationships that will assist the Company. These Board appointments will provide a solid foundation for building upon the successes of DeepOcean Group's predecessor companies and establishing the newly formed DeepOcean Group as a premier provider of subsea services as well as to complement a strong relationship between our customers, vendors and employees.”
“DeepOcean Group has a world class customer base, which we endeavor to serve safely and with the highest quality of service through our dedicated employees, strong engineering and services expertise, and excellent prospects. I am pleased to serve as the Company’s first Chairman of the Board,” said Mr. Andersen. “DeepOcean Group has a strong new Board and I am excited to work closely with these members and with the management team to capitalize on our Company's strengths and continue to build and develop our organization to realize our objectives and deliver value to all constituents involved.”
Thomas Thune Andersen:
After more than 30 years of service with the A.P. Møller-Mærsk Group, Mr. Andersen currently serves as Chairman of Lloyds Register, Vice Chairmen of VKR Holdings, and as a director on the Boards of Petrofac Ltd and Scottish & Southern Energy Plc.
Before his move from A.P. Møller-Maersk Group his last position was as Chief Executive Officer of the Oil & Gas division for Møller-Mærsk from 2004 through 2009. Prior to this position, his career in A.P. Møller-Maersk Group covered senior positions and leadership roles in the USA (CEO and President 2000 – 2004), the UK (CEO and President 1994 – 2000) and in Taiwan, Indonesia, Hong Kong and China for 13 years.
Bart H. Heijermans:
Mr. Heijermans currently serves as hedge fund advisor and manager of a start-up investment fund. With more than 20 years of global experience in subsea construction, oil and gas and deepwater operations, Mr. Heijermans was Executive Vice President and Chief Operating Officer of Helix Energy Solutions Group, Inc. and served as Chairman of CloughHelix Pty Ltd, a joint venture company focused on the provision of light construction services and well intervention in the Asia Pacific Region. Prior to that, he was Senior Vice President, Offshore and Gas Storage for Enterprise Products Partners L.P. responsible for the management of offshore pipeline and production assets and the development and execution of US$1.5 billion of organic growth deepwater infrastructure projects in the Gulf of Mexico. Previously, he held executive and senior level positions at GulfTerra Energy Partners, L.P., El Paso Corporation, Leviathan Gas Pipeline Partners L.P. and Royal Dutch Shell PLC.
Harald J. Norvik:
Mr. Norvik is an independent consultant and advisor with more than 30 years of public and private sector experience, including a large portion of his career working in senior management positions overseeing operations in offshore oil and gas markets, including subsea construction and deepwater operations. Mr. Norvik spent 11 years as CEO with Statoil during which time Statoil made the transition to private ownership. Mr. Norvik also held senior management roles with The Aker Group. He currently serves on several other Boards as Chairman or as a director, and he also served as a strategic advisor to ECON Poyry until 2011. Previously he was Chairman and Partner at ECON Management AS. Mr. Norvik also served as Deputy Minister/State Secretary for Norway’s Ministry of Petroleum and Energy from 1979 to 1981, Personal Secretary to the Prime Minister from 1976 to 1979, and has held various other positions with governmental organizations throughout his career.
Arvid Trolle:
Mr. Trolle currently serves as a Vice President at Oaktree Capital Management in London and has nearly a decade of experience in the financial services sector. Prior to joining Oaktree in 2007, Mr. Trolle worked with Mergers & Acquisitions in the Corporate Finance division at Lazard in London and prior to that Broadview International, also in London.
David N. Weinstein:
Mr. Weinstein is a consultant specializing in leveraged finance and governance issues for companies emerging from different types of reorganization and has more than 25 years of investment banking and capital markets experience. He recently served as Managing Director and Group Head, Debt Capital Markets-High Yield and Leveraged Finance for Calyon Securities Inc. and has served as the Head of High yield Capital Markets at BNP Paribas, Bank of Boston/BancBoston Securities Inc., Chase Securities Inc. and Lehman Brothers/ Smith Barney Shearson. Mr. Weinstein served as the Chairman of the Board of Directors at Pioneer Companies and York Research Corporation following their emergence from bankruptcy proceedings and was lead director of Interstate Bakeries Corporation. He currently serves on the board of directors of Georgia Gulf Corporation and Granite Broadcasting Company as well as the boards of several charitable groups involved with education and medical research.
About DeepOcean Group
DeepOcean Group is an integrated provider of subsea, trenching and marine support vessels and services dedicated to offering cutting-edge engineering solutions to customers. DeepOcean Group strives to be among the safest subsea operators in the industry and its relentless commitment to safety for its employees, without sacrificing quality service for customers, distinguishes the Company from its peers. DeepOcean Group’s subsea services and trenching/installation divisions control a well-equipped fleet of vessels and operate a fleet of modern ROVs, trenching and other subsea protection equipment. DeepOcean Group’s towing and supply division provides marine support vessels to its customers in the oil and gas industry. DeepOcean Group has a global presence including operations in the North Sea, United Kingdom, Mexico, Brazil, Southeast Asia and Australia.
Contact:
Joele Frank, Wilkinson Brimmer Katcher
Meaghan Repko / Nicholas
Lamplough, 212-355-4449
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
